Blisibimod: Ph III CHABLIS-SC1 data

Top-line data from the double-blind, international Phase III CHABLIS-SC1 trial in about 442 patients with SLE despite ongoing stable corticosteroid therapy showed that once-weekly

Read the full 244 word article

User Sign In